Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:HRTX NASDAQ:IMUX NASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$3.75$3.81$1.30▼$4.75$177.70M0.5799,797 shs68,619 shsHRTXHeron Therapeutics$0.86$0.93$0.74▼$2.30$162.55M1.72.68 million shs1.05 million shsIMUXImmunic$13.05$11.36$5.06▼$15.10$177.77M1.2288,888 shs326,555 shsMIRAMIRA Pharmaceuticals$0.99$1.04$0.90▼$2.45$41.69M1.48112,795 shs34,651 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+10.62%+1.63%+11.94%+106.04%HRTXHeron Therapeutics0.00%-0.07%-27.83%-21.21%-53.58%IMUXImmunic0.00%+11.92%+48.28%+45.27%+42.22%MIRAMIRA Pharmaceuticals0.00%+1.64%-5.52%-20.64%-18.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$3.75$3.81$1.30▼$4.75$177.70M0.5799,797 shs68,619 shsHRTXHeron Therapeutics$0.86$0.93$0.74▼$2.30$162.55M1.72.68 million shs1.05 million shsIMUXImmunic$13.05$11.36$5.06▼$15.10$177.77M1.2288,888 shs326,555 shsMIRAMIRA Pharmaceuticals$0.99$1.04$0.90▼$2.45$41.69M1.48112,795 shs34,651 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+10.62%+1.63%+11.94%+106.04%HRTXHeron Therapeutics0.00%-0.07%-27.83%-21.21%-53.58%IMUXImmunic0.00%+11.92%+48.28%+45.27%+42.22%MIRAMIRA Pharmaceuticals0.00%+1.64%-5.52%-20.64%-18.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 3.00Buy$8.00113.33% UpsideHRTXHeron Therapeutics 2.20Hold$4.50423.99% UpsideIMUXImmunic 3.00Buy$47.57264.53% UpsideMIRAMIRA Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest MIRA, ADAG, HRTX, and IMUX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026IMUXImmunic Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/22/2026IMUXImmunic B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $27.005/14/2026IMUXImmunic Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/4/2026IMUXImmunic Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026IMUXImmunic HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00 ➝ $22.004/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ADAGAdagene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026IMUXImmunic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$25.004/15/2026IMUXImmunic D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$7.67M23.17N/AN/A$0.75 per share5.00HRTXHeron Therapeutics$154.90M1.05N/AN/A$0.04 per share21.47IMUXImmunicN/AN/AN/AN/A$11.10 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$17.61MN/AN/AN/AN/AN/AN/AN/AN/AHRTXHeron Therapeutics-$20.19M-$0.18N/A7.16N/A-20.53%-7,747.30%-8.94%8/11/2026 (Estimated)IMUXImmunic-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%8/6/2026 (Estimated)MIRAMIRA Pharmaceuticals-$10.44M-$1.30N/AN/AN/AN/A-140.82%-135.01%6/3/2026 (Estimated)Latest MIRA, ADAG, HRTX, and IMUX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MIRAMIRA PharmaceuticalsN/A-$0.03N/A-$0.03N/AN/A5/13/2026Q1 2026IMUXImmunic-$0.71-$1.08-$0.37-$1.08N/AN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million4/1/2026Q4 2025ADAGAdagene-$0.28-$0.0440+$0.2360-$0.0440$17.50 million$3.84 million2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 million2/26/2026Q4 2025IMUXImmunic-$1.0222-$1.20-$0.1778-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.033.073.07HRTXHeron Therapeutics17.512.531.51IMUXImmunicN/A4.924.92MIRAMIRA PharmaceuticalsN/A82.1582.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%HRTXHeron Therapeutics80.01%IMUXImmunic51.82%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%HRTXHeron Therapeutics5.86%IMUXImmunic14.00%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.39 million37.34 millionNot OptionableHRTXHeron Therapeutics300189.28 million178.19 millionOptionableIMUXImmunic7013.62 million11.72 millionOptionableMIRAMIRA Pharmaceuticals242.02 million39.23 millionNot OptionableMIRA, ADAG, HRTX, and IMUX HeadlinesRecent News About These CompaniesMira Pharmaceuticals stock gains on Phase 1 trial resultsMay 14, 2026 | investing.comMIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2May 14, 2026 | accessnewswire.comAMIRA highlights SKNY-1 preclinical data in new publicationMay 13, 2026 | tipranks.comMIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug CandidateMay 13, 2026 | accessnewswire.comAVisionstate Reports 27% Q2 Revenue Growth as MIRA Platform Gains TractionMay 6, 2026 | newsfilecorp.comNWhat's going on with MIRA Pharma stock Tuesday?March 24, 2026 | msn.comMIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55March 23, 2026 | tipranks.comMIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical StudiesMarch 23, 2026 | accessnewswire.comAMIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trialMarch 5, 2026 | yahoo.comMIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2March 4, 2026 | accessnewswire.comAMIRA Completes Phase 1 Trial of Ketamir-2 TherapyMarch 3, 2026 | tipranks.comWhy MIRA Pharmaceuticals, Inc.’s (MIRA) Stock Is Down 13.39%March 3, 2026 | aaii.comAVisionstate Repositions Under MIRA Compliance Platform and Reports Subscription GrowthFebruary 19, 2026 | newsfilecorp.comNMIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a StudyFebruary 3, 2026 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final CohortFebruary 2, 2026 | tipranks.comMIRA Pharmaceuticals Expands Stock Offering by $15MDecember 5, 2025 | tipranks.comMIRA Pharmaceuticals (MIRA) Price Target Decreased by 83.10% to 3.06October 29, 2025 | msn.comMIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a IndicationOctober 24, 2025 | accessnewswire.comAMIRA Pharmaceuticals Advances Ketamir-2 Clinical TrialsOctober 23, 2025 | tipranks.comMira Pharmaceuticals announces preclinical data on oral Mira-55October 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026MIRA, ADAG, HRTX, and IMUX Company DescriptionsAdagene NASDAQ:ADAG$3.75 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.74 0.00 (-0.13%) As of 05/22/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Heron Therapeutics NASDAQ:HRTX$0.86 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.86 +0.00 (+0.14%) As of 05/22/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Immunic NASDAQ:IMUX$13.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.64 -0.41 (-3.16%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.MIRA Pharmaceuticals NASDAQ:MIRA$0.99 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.71%) As of 05/22/2026 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
